182 related articles for article (PubMed ID: 24397848)
21. In-Silico docking of HIV-1 integrase inhibitors reveals a novel drug type acting on an enzyme/DNA reaction intermediate.
Savarino A
Retrovirology; 2007 Mar; 4():21. PubMed ID: 17374162
[TBL] [Abstract][Full Text] [Related]
22. Diketoacid inhibitors of HIV-1 integrase: from L-708,906 to raltegravir and beyond.
Beare KD; Coster MJ; Rutledge PJ
Curr Med Chem; 2012; 19(8):1177-92. PubMed ID: 22214459
[TBL] [Abstract][Full Text] [Related]
23. THAP9 Transposase Cleaves DNA via Conserved Acidic Residues in an RNaseH-Like Domain.
Sharma V; Thakore P; Majumdar S
Cells; 2021 May; 10(6):. PubMed ID: 34072453
[TBL] [Abstract][Full Text] [Related]
24. Natural stilbenoids isolated from grapevine exhibiting inhibitory effects against HIV-1 integrase and eukaryote MOS1 transposase in vitro activities.
Pflieger A; Waffo Teguo P; Papastamoulis Y; Chaignepain S; Subra F; Munir S; Delelis O; Lesbats P; Calmels C; Andreola ML; Merillon JM; Auge-Gouillou C; Parissi V
PLoS One; 2013; 8(11):e81184. PubMed ID: 24312275
[TBL] [Abstract][Full Text] [Related]
25. HIV-1 group O integrase displays lower enzymatic efficiency and higher susceptibility to raltegravir than HIV-1 group M subtype B integrase.
Depatureaux A; Quashie PK; Mesplède T; Han Y; Koubi H; Plantier JC; Oliveira M; Moisi D; Brenner B; Wainberg MA
Antimicrob Agents Chemother; 2014 Dec; 58(12):7141-50. PubMed ID: 25224008
[TBL] [Abstract][Full Text] [Related]
26. Rigidity and flexibility characteristics of DD[E/D]-transposases Mos1 and Sleeping Beauty.
Singer CM; Joy D; Jacobs DJ; Nesmelova IV
Proteins; 2019 Apr; 87(4):313-325. PubMed ID: 30582767
[TBL] [Abstract][Full Text] [Related]
27. Solution conformation and dynamics of the HIV-1 integrase core domain.
Fitzkee NC; Masse JE; Shen Y; Davies DR; Bax A
J Biol Chem; 2010 Jun; 285(23):18072-84. PubMed ID: 20363759
[TBL] [Abstract][Full Text] [Related]
28. Investigating the role of metal chelation in HIV-1 integrase strand transfer inhibitors.
Bacchi A; Carcelli M; Compari C; Fisicaro E; Pala N; Rispoli G; Rogolino D; Sanchez TW; Sechi M; Sinisi V; Neamati N
J Med Chem; 2011 Dec; 54(24):8407-20. PubMed ID: 22066494
[TBL] [Abstract][Full Text] [Related]
29. Crystal structures of catalytic core domains of retroviral integrases and role of divalent cations in enzymatic activity.
Wlodawer A
Adv Virus Res; 1999; 52():335-50. PubMed ID: 10384241
[TBL] [Abstract][Full Text] [Related]
30. Reduced HIV-1 integrase flexibility as a mechanism for raltegravir resistance.
Dewdney TG; Wang Y; Kovari IA; Reiter SJ; Kovari LC
J Struct Biol; 2013 Nov; 184(2):245-50. PubMed ID: 23891838
[TBL] [Abstract][Full Text] [Related]
31. Treatment with suboptimal doses of raltegravir leads to aberrant HIV-1 integrations.
Varadarajan J; McWilliams MJ; Hughes SH
Proc Natl Acad Sci U S A; 2013 Sep; 110(36):14747-52. PubMed ID: 23959861
[TBL] [Abstract][Full Text] [Related]
32. HIV‑1 integrase inhibitors targeting various DDE transposases: Retroviral integration versus RAG‑mediated recombination (Review).
Mușat MG; Nițulescu GM; Surleac M; Tsatsakis A; Spandidos DA; Margină D
Mol Med Rep; 2019 Dec; 20(6):4749-4762. PubMed ID: 31702817
[TBL] [Abstract][Full Text] [Related]
33. A dynamic model of HIV integrase inhibition and drug resistance.
Perryman AL; Forli S; Morris GM; Burt C; Cheng Y; Palmer MJ; Whitby K; McCammon JA; Phillips C; Olson AJ
J Mol Biol; 2010 Mar; 397(2):600-15. PubMed ID: 20096702
[TBL] [Abstract][Full Text] [Related]
34. The catalytic domain of avian sarcoma virus integrase: conformation of the active-site residues in the presence of divalent cations.
Bujacz G; Jaskólski M; Alexandratos J; Wlodawer A; Merkel G; Katz RA; Skalka AM
Structure; 1996 Jan; 4(1):89-96. PubMed ID: 8805516
[TBL] [Abstract][Full Text] [Related]
35. Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143.
Métifiot M; Vandegraaff N; Maddali K; Naumova A; Zhang X; Rhodes D; Marchand C; Pommier Y
AIDS; 2011 Jun; 25(9):1175-8. PubMed ID: 21505303
[TBL] [Abstract][Full Text] [Related]
36. Unexpected structural diversity in DNA recombination: the restriction endonuclease connection.
Hickman AB; Li Y; Mathew SV; May EW; Craig NL; Dyda F
Mol Cell; 2000 Jun; 5(6):1025-34. PubMed ID: 10911996
[TBL] [Abstract][Full Text] [Related]
37. Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy.
Lewis MG; Norelli S; Collins M; Barreca ML; Iraci N; Chirullo B; Yalley-Ogunro J; Greenhouse J; Titti F; Garaci E; Savarino A
Retrovirology; 2010 Mar; 7():21. PubMed ID: 20233398
[TBL] [Abstract][Full Text] [Related]
38. Tn5 transposase as a useful platform to simulate HIV-1 integrase inhibitor binding mode.
Barreca ML; Ortuso F; Iraci N; De Luca L; Alcaro S; Chimirri A
Biochem Biophys Res Commun; 2007 Nov; 363(3):554-60. PubMed ID: 17889829
[TBL] [Abstract][Full Text] [Related]
39. Transposase-transposase interactions in MOS1 complexes: a biochemical approach.
Carpentier G; Jaillet J; Pflieger A; Adet J; Renault S; Augé-Gouillou C
J Mol Biol; 2011 Jan; 405(4):892-908. PubMed ID: 21110982
[TBL] [Abstract][Full Text] [Related]
40. Retroviral intasome assembly and inhibition of DNA strand transfer.
Hare S; Gupta SS; Valkov E; Engelman A; Cherepanov P
Nature; 2010 Mar; 464(7286):232-6. PubMed ID: 20118915
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
